Literature DB >> 29401272

Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure.

Aida Valmaseda1, Eusebio Macete2, Augusto Nhabomba2, Caterina Guinovart1, Pedro Aide2, Azucena Bardají1, Quique Bassat1,2,3,4, Tacilta Nhampossa2, Sonia Maculuve2, Aina Casellas1, Llorenç Quintó1, Sergi Sanz1, Alfons Jiménez1,5, Gaoqian Feng6, Christine Langer6, Linda Reiling6, K Sony Reddy7, Alok Pandey7, Chetan E Chitnis8, Virander S Chauhan7, Ruth Aguilar1, John J Aponte1,2, Carlota Dobaño1, James G Beeson6,9, Deepak Gaur10, Clara Menéndez1,2,5, Pedro L Alonso1,2, Alfredo Mayor1,2.   

Abstract

Background: A main criterion to identify malaria vaccine candidates is the proof that acquired immunity against them is associated with protection from disease. The age of the studied individuals, heterogeneous malaria exposure, and assumption of the maintenance of a baseline immune response can confound these associations.
Methods: Immunoglobulin G/immunoglobulin M (IgG/ IgM) levels were measured by Luminex® in Mozambican children monitored for clinical malaria from birth until 3 years of age, together with functional antibodies. Studied candidates were pre-erythrocytic and erythrocytic antigens, including EBAs/PfRhs, MSPs, DBLs, and novel antigens merely or not previously studied in malaria-exposed populations. Cox regression models were estimated at 9 and 24 months of age, accounting for heterogeneous malaria exposure or limiting follow-up according to the antibody's decay.
Results: Associations of antibody responses with higher clinical malaria risk were avoided when accounting for heterogeneous malaria exposure or when limiting the follow-up time in the analyses. Associations with reduced risk of clinical malaria were found only at 24 months old, but not younger children, for IgG breadth and levels of IgG targeting EBA140III-V, CyRPA, DBL5ε and DBL3x, together with C1q-fixation activity by antibodies targeting MSP119. Conclusions: Malaria protection correlates were identified, only in children aged 24 months old when accounting for heterogeneous malaria exposure. These results highlight the relevance of considering age and malaria exposure, as well as the importance of not assuming the maintenance of a baseline immune response throughout the follow-up. Results may be misleading if these factors are not considered.
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibodies; correlates of protection; heterogeneity in malaria exposure; malaria; vaccines

Mesh:

Substances:

Year:  2018        PMID: 29401272     DOI: 10.1093/cid/cix837

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M.

Authors:  Damian A Oyong; Danny W Wilson; Bridget E Barber; Timothy William; Jianlin Jiang; Mary R Galinski; Freya J I Fowkes; Matthew J Grigg; James G Beeson; Nicholas M Anstey; Michelle J Boyle
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

2.  Plasmodium falciparum Cysteine-Rich Protective Antigen (CyRPA) Elicits Detectable Levels of Invasion-Inhibitory Antibodies during Natural Infection in Humans.

Authors:  Syed Yusuf Mian; Anjali Somanathan; Kritika Chaddha; Alok K Pandey; Hina Singh; Sri Krishna; Neha Chaturvedi; Seemalata Uchoi; Man Mohan Shukla; Praveen K Bharti; Neeru Singh; Virander Singh Chauhan; Deepak Gaur
Journal:  Infect Immun       Date:  2021-10-25       Impact factor: 3.609

3.  Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.

Authors:  Rafiou Adamou; Célia Dechavanne; Ibrahim Sadissou; Tania d'Almeida; Aziz Bouraima; Paulin Sonon; Roukiyath Amoussa; Gilles Cottrell; Agnès Le Port; Michael Theisen; Edmond J Remarque; Shirley Longacre; Kabirou Moutairou; Achille Massougbodji; Adrian J F Luty; Gregory Nuel; Florence Migot-Nabias; Ambaliou Sanni; André Garcia; Jacqueline Milet; David Courtin
Journal:  Malar J       Date:  2019-06-11       Impact factor: 2.979

4.  Targets of complement-fixing antibodies in protective immunity against malaria in children.

Authors:  Linda Reiling; Michelle J Boyle; Michael T White; Danny W Wilson; Gaoqian Feng; Rupert Weaver; D Herbert Opi; Kristina E M Persson; Jack S Richards; Peter M Siba; Freya J I Fowkes; Eizo Takashima; Takafumi Tsuboi; Ivo Mueller; James G Beeson
Journal:  Nat Commun       Date:  2019-02-05       Impact factor: 14.919

5.  RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study.

Authors:  Carlota Dobaño; Itziar Ubillos; Chenjerai Jairoce; Ben Gyan; Marta Vidal; Alfons Jiménez; Rebeca Santano; David Dosoo; Augusto J Nhabomba; Aintzane Ayestaran; Ruth Aguilar; Nana Aba Williams; Núria Díez-Padrisa; David Lanar; Virander Chauhan; Chetan Chitnis; Sheetij Dutta; Deepak Gaur; Evelina Angov; Kwaku Poku Asante; Seth Owusu-Agyei; Clarissa Valim; Benoit Gamain; Ross L Coppel; David Cavanagh; James G Beeson; Joseph J Campo; Gemma Moncunill
Journal:  BMC Med       Date:  2019-08-14       Impact factor: 8.775

6.  Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity.

Authors:  Isaac Ssewanyana; John Rek; Isabel Rodriguez; Lindsey Wu; Emmanuel Arinaitwe; Joaniter I Nankabirwa; James G Beeson; Harriet Mayanja-Kizza; Philip J Rosenthal; Grant Dorsey; Moses R Kamya; Chris Drakeley; Bryan Greenhouse; Kevin K A Tetteh
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

Review 7.  Strategies for Immunomonitoring after Vaccination and during Infection.

Authors:  Lucille Adam; Pierre Rosenbaum; Olivia Bonduelle; Behazine Combadière
Journal:  Vaccines (Basel)       Date:  2021-04-09

8.  Microscopic and submicroscopic infection by Plasmodium falciparum: Immunoglobulin M and A profiles as markers of intensity and exposure.

Authors:  Paloma Abad; Patricia Marín-García; Marcos Heras; Julius N Fobil; Alfred G Hutchful; Amalia Diez; Antonio Puyet; Armando Reyes-Palomares; Isabel G Azcárate; José M Bautista
Journal:  Front Cell Infect Microbiol       Date:  2022-09-02       Impact factor: 6.073

9.  Process development and preclinical evaluation of a major Plasmodium falciparum blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA).

Authors:  Anjali Somanathan; Syed Yusuf Mian; Kritika Chaddha; Seemalata Uchoi; Praveen K Bharti; Ravi Tandon; Deepak Gaur; Virander Singh Chauhan
Journal:  Front Immunol       Date:  2022-09-22       Impact factor: 8.786

10.  Antibody Combinations Targeting the Essential Antigens CyRPA, RH5, and MSP-119 Potently Neutralize Plasmodium falciparum Clinical Isolates From India and Africa.

Authors:  Hina Singh; Syed Yusuf Mian; Alok K Pandey; Sri Krishna; Gaurav Anand; K Sony Reddy; Neha Chaturvedi; Vanndita Bahl; Nidhi Hans; Man Mohan Shukla; Quique Bassat; Alfredo Mayor; Kazutoyo Miura; Praveen K Bharti; Carole Long; Neeru Singh; Virander Singh Chauhan; Deepak Gaur
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.